- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 178
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 125,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Obesity
- Interventions
- Survodutide
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Riverview, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 70,000 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes, Overweight, Cardiovascular (CV) Risk
- Interventions
- Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 887,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators
- Interventions
- GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
- Drug · Behavioral
- Lead sponsor
- Jing Luo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Endometrial Cancer, Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Obesity, Overweight and Obesity, Overweight
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Overweight, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 54
- States / cities
- Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Covina, California + 51 more
- Conditions
- Healthy
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Overweight and Obesity
- Interventions
- Apitegromab, Placebo, Tirzepatide
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Orlando, Florida • Chicago, Illinois + 4 more
- Conditions
- Healthy
- Interventions
- Tirzepatide, EE/NGM
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Northridge, California • Aurora, Colorado • Denver, Colorado + 7 more
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor
- Interventions
- Noom Weight, Free Tier, Education-only control, Semaglutide, Tirzepatide, Microdose semaglutide, Microdose tirzepatide
- Behavioral · Drug
- Lead sponsor
- Noom Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 2,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Severe Obesity, Obesity, BMI Greater Than 30
- Interventions
- Tirzepatide, Standard of Care post-gastric bypass
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Psoriatic Arthritis, Overweight or Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
- Conditions
- Obesity
- Interventions
- Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo
- Drug
- Lead sponsor
- BioAge Labs, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Mesa, Arizona • Los Angeles, California • Montclair, California + 11 more
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Interventions
- Tirzepatide, Acetaminophen
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Obesity
- Interventions
- Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide, Naltrexone-Bupropion, Phentermine-Topiramate, Semaglutide (Wegovy®)
- Other · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
- Interventions
- Gastric Fundal Mucosal Ablation (GFMA)
- Device
- Lead sponsor
- Dr. Christopher McGowan
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Type 1 Diabetes, Obesity, Overweight
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 31
- States / cities
- Santa Barbara, California • Santa Clarita, California • Aurora, Colorado + 27 more
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
- Interventions
- Metabolic surgery, Incretin-Based Therapy
- Procedure · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more
- Conditions
- Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28,118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts